Focus: Ironwood Pharmaceuticals is a specialty pharmaceutical company headquartered in Boston focused on small-molecule therapeutics, primarily in gastrointestinal and metabolic indications. The company markets established products like Linzess (linaclotide) and maintains a diversified pipeline across Phase 2–4 development.
Profile data last refreshed 13h ago · AI intelligence enriched 2w ago
Stable — net +4 jobs in 30d
4 added, 0 removed. Backfill posture.
Ironwood offers relative stability and established market presence but faces patent cliff headwinds and constrained hiring, making it suitable for mid-career candidates seeking specialty pharma experience over growth-stage opportunity.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Xanthine oxidase inhibitor at peak commercial maturity with 6-year LOE runway; faces generic erosion risk post-2032.
Help build intelligence for Ironwood Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Ironwood Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Dual-mechanism fixed-dose combination for gout management; both components face patent expiration in 2032, creating significant revenue cliff risk.
Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - Buy - Seeking Alpha
Ironwood Pharmaceuticals: The Stock Is A Call On The Second Apraglutide Trial - Buy Seeking Alpha
Ironwood’s 30-year medical chief retires as Phase 3 trial recruits - Stock Titan
Ironwood’s 30-year medical chief retires as Phase 3 trial recruits Stock Titan
Ironwood Pharmaceuticals Stock - Analyst snapshot and sector review at week’s end - Ad-hoc-news.de
Ironwood Pharmaceuticals Stock - Analyst snapshot and sector review at week’s end Ad-hoc-news.de
Is Ironwood Pharmaceuticals, Inc. (IRWD) Strengthening Its Growth Outlook With Expanded Pediatric Approval for Linzess? - Yahoo Finance
Is Ironwood Pharmaceuticals, Inc. (IRWD) Strengthening Its Growth Outlook With Expanded Pediatric Approval for Linzess? Yahoo Finance
Ironwood Pharmaceuticals, Inc. (IRWD) stock price, news, quote and history - Yahoo Finance UK
Ironwood Pharmaceuticals, Inc. (IRWD) stock price, news, quote and history Yahoo Finance UK
Ironwood Pharmaceuticals (IRWD) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Ironwood Pharmaceuticals (IRWD) FDA Approvals, PDUFA Dates & Drug Alerts 2026 MarketBeat
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
No publicly disclosed FDA warnings or product shortages; primary risk stems from 2032 patent cliff and recent C-suite turnover, warranting due diligence on pipeline advancement and retention stability.
Recent peer-reviewed publications with author affiliations at this company
Patient and healthcare professional perspectives on short bowel syndrome management and preferred treatment attributes: Results from the Landmark survey study.
A post hoc analysis of linaclotide in pediatric patients with functional constipation and neurodevelopmental disorders.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo